Core Viewpoint - The company plans to repurchase and cancel 20,000 restricted stocks due to certain incentive recipients no longer meeting the eligibility criteria outlined in the 2021 restricted stock incentive plan [2][4]. Group 1: Repurchase and Cancellation Details - The decision for the repurchase and cancellation of restricted stocks was approved during the fifth board meeting on April 28, 2025, following the authorization from the first extraordinary general meeting of shareholders in 2021 [2][4]. - The repurchase involves 6 incentive recipients who will have their unvested restricted stocks canceled [5]. - The company has opened a dedicated securities account for the repurchase and submitted the application for cancellation, expecting to complete the process by August 1, 2025 [5]. Group 2: Legal and Compliance Aspects - The board confirms that the decision-making process and information disclosure comply with relevant laws and regulations, ensuring no harm to the rights of incentive recipients or creditors [7]. - A legal opinion from a law firm confirms that the repurchase has obtained necessary authorizations and complies with applicable laws and regulations [7].
海利尔药业集团股份有限公司 关于股权激励限制性股票回购注销实施的公告